SPRB - SPRUCE BIOSCIENCES, INC.

0.2737
-0.007   -2.521%

Share volume: 358,742
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.28
-0.01
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
16%
Profitability 0%
Dept financing 32%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.49%
1 Month
-21.58%
3 Months
-27.97%
6 Months
-39.18%
1 Year
-65.35%
2 Year
-86.45%
Key data
Stock price
$0.27
P/E Ratio 
0.00
DAY RANGE
$0.26 - $0.29
EPS 
-$0.50
52 WEEK RANGE
$0.26 - $0.87
52 WEEK CHANGE
-$64.38
MARKET CAP 
19.615 M
YIELD 
N/A
SHARES OUTSTANDING 
41.303 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$547,288
AVERAGE 30 VOLUME 
$275,643
Company detail
CEO: Javier Szwarcberg
Region: US
Website: www.sprucebiosciences.com
Employees: 20
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Spruce Biosciences, Inc. focuses on developing and commercializing novel therapies for rare endocrine disorders. The company is developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia.

Recent news
loading